Referenzen

[1] Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996 Jul;24(7):1125-8.

[2] Till U. Pathophysiologie / Pathobiochemie systematisch. 1. Auflage. Uni-Med 1999.

[3] Kayser FH, Bienz KA, Eckert J, Zinkernagel RM. Medizinische Mikrobiologie. 10. Auflage. Thieme 2001.

[4] American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992 Jun;20(6):864-74.

[5] Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003 Apr;29(4):530-8.

[6] Astiz ME, Rackow EC. Septic shock. Lancet. 1998 May;351(9114):1501-5.

[7] Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997 Jul;112(1):235-43.

[8] Haveman JW, Muller Kobold AC, Tervaert JW, van den Berg AP, Tulleken JE, Kallenberg CG, The TH. The central role of monocytes in the pathogenesis of sepsis: consequences for immunomonitoring and treatment. Neth J Med. 1999 Sep;55(3):132-41.

[9] www.sepsis-gesellschaft.de

[10] Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 Jul;29(7):1303-10.

[11] Moerer O, Schmid A, Hofmann M, Herklotz A, Reinhart K, Werdan K, Schneider H, Burchardi H. Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med. 2002 Oct;28(10):1440-6.

[12] Cohen J. The immunopathogenesis of sepsis. Nature. 2002 Dec;420(6917):885-91.

[13] Schumann R, Zweigner J. A novel Acute-Phase Marker: Lipopolysaccharide Binding Protein (LBP). Clin Chem Lab Med. 1999; 37(3):271-4.

[14] Ludemann J, Schulte KL, Hader O, Brehme S, Volk HD, Docke WD. Leukocyte/endothelium activation and interactions during femoral percutaneous transluminal angioplasty. Vasc Surg. 2001 Jul-Aug;35(4):293-301.

[15] Smedly LA, Tonnesen MG, Sandhaus RA, Haslett C, Guthrie LA, Johnston RB Jr, Henson PM, Worthen GS. Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest. 1986 Apr;77(4):1233-43.

[16] Wakefield CH, Carey PD, Foulds S, Monson JR, Guillou PJ. Polymorphonuclear leukocyte activation. An early marker of the postsurgical sepsis response. Arch Surg. 1993 Apr;128(4):390-5.

[17] Takala A, Jousela I, Jansson SE, Olkkola KT, Takkunen O, Orpana A, Karonen SL, Repo H. Markers of systemic inflammation predicting organ failure in community-acquired septic shock. Clin Sci (Lond). 1999 Nov;97(5):529-38.

[18] Lin RY, Astiz ME, Saxon JC, Rackow EC. Altered leukocyte immunophenotypes in septic shock. Studies of HLA-DR, CD11b, CD14, and IL-2R expression. Chest. 1993 Sep;104(3):847-53.

[19] Maekawa K, Futami S, Nishida M, Terada T, Inagawa H, Suzuki S, Ono K. Effects of trauma and sepsis on soluble L-selectin and cell surface expression of L-selectin and CD11b. J Trauma. 1998 Mar;44(3):460-8.

[20] Takala A, Jousela I, Olkkola KT, Jansson SE, Leirisalo-Repo M, Takkunen O, Repo H. Systemic inflammatory response syndrome without systemic inflammation in acutely ill patients admitted to hospital in a medical emergency. Clin Sci (Lond). 1999 Mar;96(3):287-95.

[21] Russwurm S, Vickers J, Meier-Hellmann A, Spangenberg P, Bredle D, Reinhart K, Losche W. Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock. 2002 Apr;17(4):263-8.

[22] Muller Kobold AC, Tulleken JE, Zijlstra JG, Sluiter W, Hermans J, Kallenberg CG, Tervaert JW. Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med. 2000 Jul;26(7):883-92.

[23] Davis BH, Bigelow NC, Curnutte JT, Ornvold K. Neutrophil CD64 expression: Potential diagnostic indicator of acute inflammation and therapeutic monitor of interferon gamma therapy. Lab Hem. 1995;1:3-12.

[24] Qureshi SS, Lewis SM, Gant VA, Treacher D, Davis BH, Brown KA. Increased distribution and expression of CD64 on blood polymorphonuclear cells from patients with the systemic inflammatory response syndrome (SIRS). Clin Exp Immunol. 2001 Aug;125(2):258-65.

[25] Fischer G, Schneider EM, L Moldawer LL, Karcher C, Barth E, Suger-Wiedeck H, Georgieff M, Weiss M. CD64 surface expression on neutrophils is transiently upregulated in patients with septic shock. Intensive Care Med. 2001 Dec;27(12):1848-52.

[26] Hirsh M, Mahamid E, Bashenko Y, Hirsh I, Krausz MM. Overexpression of the high-affinity Fcgamma receptor (CD64) is associated with leukocyte dysfunction in sepsis. Shock. 2001 Aug;16(2):102-8.

[27] Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995 Jan;273(2):117-23.

[28] Rodriguez-Gaspar M, Santolaria F, Jarque-Lopez A, Gonzalez-Reimers E, Milena A, de la Vega MJ, Rodriguez-Rodriguez E, Gomez-Sirvent JL. Prognostic value of cytokines in SIRS general medical patients. Cytokine. 2001 Aug;15(4):232-6.

[29] Chishti AD, Shenton BK, Kirby JA, Baudouin SV. Neutrophil chemotaxis and receptor expression in clinical septic shock. Intensive Care Med. 2004 Apr;30(4):605-11.

[30] van der Poll T. Immunotherapy of sepsis. Lancet Infect Dis. 2001 Oct;1(3):165-74.

[31] Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995 Mar;273(12):934-41.

[32] Woiciechowsky C, Schoning B, Lanksch WR, Volk HD, Docke WD. Mechanisms of brain-mediated systemic anti-inflammatory syndrome causing immunodepression. J Mol Med. 1999 Nov;77(11):769-80.

[33] Volk HD, Reinke P, Falck P, Staffa G, Briedigkeit H, v. Baehr R. Diagnostic value of an immune monitoring program for the clinical management of immunosuppressed patients with septic complications. Clin Transplantation. 1989;3:246-52.

[34] Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997 Jun;3(6):678-81.

[35] Volk HD, Thieme M, Heym S, Docke WD, Ruppe U, Tausch W, Manger D, Zuckermann S, Golosubow A, Nieter B, et al. Alterations in function and phenotype of monocytes from patients with septic disease--predictive value and new therapeutic strategies. Behring Inst Mitt. 1991 Feb;(88):208-15.

[36] Wakefield CH, Carey PD, Foulds S, Monson JR, Guillou PJ. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg. 1993 Feb;80(2):205-9.

[37] van den Berk JM, Oldenburger RH, van den Berg AP, Klompmaker IJ, Mesander G, van Son WJ, van der Bij W, Sloof MJ, The TH. Low HLA-DR expression on monocytes as a prognostic marker for bacterial sepsis after liver transplantation. Transplantation. 1997 Jun;63(12):1846-8.

[38] Manjuck J, Saha DC, Astiz M, Eales LJ, Rackow EC. Decreased response to recall antigens is associated with depressed costimulatory receptor expression in septic critically ill patients. J Lab Clin Med. 2000 Feb;135(2):153-60.

[39] Guillou PJ. Biological variation in the development of sepsis after surgery or trauma. Lancet. 1993 Jul;342(8865):217-20.

[40] Kox WJ, Bone RC, Krausch D, Docke WD, Kox SN, Wauer H, Egerer K, Querner S, Asadullah K, von Baehr R, Volk HD. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med. 1997 Feb;157(4):389-93.

[41] Randow F, Syrbe U, Meisel C, Krausch D, Zuckermann H, Platzer C, Volk HD. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med. 1995 May;181(5):1887-92.

[42] Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med. 1991 Dec;174(6):1549-55.

[43] de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991 Nov;174(5):1209-20.

[44] Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, Trentz O, Schildberg FW. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood. 1995 Mar;85(5):1341-7.

[45] Klava A, Windsor AC, Farmery SM, Woodhouse LF, Reynolds JV, Ramsden CW, Boylston AW, Guillou PJ. Interleukin-10. A role in the development of postoperative immunosuppression. Arch Surg. 1997 Apr;132(4):425-9.

[46] Fumeaux T, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Crit Care Med. 2002 Dec;166(11):1475-82.

[47] Borovikova LV, Ivanova S, Nardi D, Zhang M, Yang H, Ombrellino M, Tracey KJ. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton Neurosci. 2000 Dec;85(1-3):141-7.

[48] Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000 May;405(6785):458-62.

[49] Tracey KJ. The inflammatory reflex. Nature. 2002 Dec;420(6917):853-9.

[50] Asadullah K, Woiciechowsky C, Docke WD, Liebenthal C, Wauer H, Kox W, Volk HD, Vogel S, Von Baehr R. Immunodepression following neurosurgical procedures. Crit Care Med. 1995 Dec;23(12):1976-83.

[51] Tran DD, Groeneveld AB, van der Meulen J, Nauta JJ, Strack van Schijndel RJ, Thijs LG. Age, chronic disease, sepsis, organ system failure, and mortality in a medical intensive care unit. Crit Care Med. 1990 May;18(5):474-9.

[52] Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA. 1995 Sep;274(12):968-74.

[53] Gando S, Nanzaki S, Kemmotsu O. Disseminated intravascular coagulation and sustained systemic inflammatory response syndrome predict organ dysfunctions after trauma: application of clinical decision analysis. Ann Surg. 1999 Jan;229(1):121-7.

[54] Bochicchio GV, Napolitano LM, Joshi M, Knorr K, Tracy JK, Ilahi O, Scalea TM. Persistent systemic inflammatory response syndrome is predictive of nosocomial infection in trauma. J Trauma. 2002 Aug;53(2):245-50.

[55] Henne-Bruns D, Dürig M, Kremer B. Chirurgie. 2. Auflage. Thieme 2003.

[56] Westaby S. Complement and the damaging effect of cardiopulmonary bypass. Thorax. 1983 May;38(5):321-5.

[57] Hall RI, Smith MS, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg. 1997 Oct;85(4):766-82.

[58] Markewitz A, Lante W, Franke A, Marohl K, Kuhlmann WD, Weinhold C. Alterations of cell-mediated immunity following cardiac operations: clinical implications and open questions. Shock. 2001;16 Suppl 1:10-5.

[59] Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993 Feb;55(2):552-9.

[60] Landow L, Andersen LW. Splanchnic ischaemia and its role in multiple organ failure. Acta Anaesthesiol Scand. 1994 Oct;38(7):626-39.

[61] McBride WT, Armstrong MA, Crockard AD, McMurray TJ, Rea JM. Cytokine balance and immunosuppressive changes at cardiac surgery: contrasting response between patients and isolated CPB circuits. Br J Anaesth. 1995 Dec;75(6):724-33.

[62] Kawamura T, Wakusawa R, Inada K. Interleukin-10 and interleukin-1 receptor antagonists increase during cardiac surgery. Can J Anaesth. 1997 Jan;44(1):38-42.

[63] Kharazmi A, Andersen LW, Baek L, Valerius NH, Laub M, Rasmussen JP. Endotoxemia and enhanced generation of oxygen radicals by neutrophils from patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1989 Sep;98(3):381-5.

[64] Butler J, Parker D, Pillai R, Westaby S, Shale DJ, Rocker GM. Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor. J Thorac Cardiovasc Surg. 1993 Jan;105(1):25-30.

[65] Hill GE. Cardiopulmonary bypass-induced inflammation: is it important? J Cardiothorac Vasc Anesth. 1998 Apr;12(2 Suppl 1):21-5.

[66] Wildhirt SM, Schulze C, Schulz C, Egi K, Brenner P, Mair H, Schutz A, Reichart B. Reduction of systemic and cardiac adhesion molecule expression after off-pump versus conventional coronary artery bypass grafting. Shock. 2001;16 Suppl 1:55-9.

[67] Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1983 Dec;86(6):845-57.

[68] Okubo N, Hatori N, Ochi M, Tanaka S. Comparison of m-RNA expression for inflammatory mediators in leukocytes between on-pump and off-pump coronary artery bypass grafting. Ann Thorac Cardiovasc Surg. 2003 Feb;9(1):43-9.

[69] Al-Ruzzeh S, Hoare G, Marczin N, Asimakopoulos G, George S, Taylor K, Amrani M. Off-pump coronary artery bypass surgery is associated with reduced neutrophil activation as measured by the expression of CD11b: a prospective randomized study. Heart Surg Forum. 2003;6(2):89-93.

[70] Michalopoulos A, Stavridis G, Geroulanos S. Severe sepsis in cardiac surgical patients. Eur J Surg. 1998 Mar;164(3):217-22.

[71] Higgins TL, Estafanous FG, Loop FD, Beck GJ, Blum JM, Paranandi L. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score. JAMA. 1992 May;267(17):2344-8. Erratum in: JAMA 1992 Oct 14;268(14):1860.

[72] Rinder CS, Mathew JP, Rinder HM, Tracey JB, Davis E, Smith BR. Lymphocyte and monocyte subset changes during cardiopulmonary bypass: effects of aging and gender. J Lab Clin Med. 1997 Jun;129(6):592-602.

[73] Orita H, Shimanuki T, Fukasawa M, Inui K, Goto S, Washio M, Horikawa H. A clinical study of postoperative infections following open-heart surgery: occurrence and microbiological findings in 782 cases. Surg Today. 1992;22(3):207-12.

[74] Bossink AW, Groeneveld J, Hack CE, Thijs LG. Prediction of mortality in febrile medical patients: How useful are systemic inflammatory response syndrome and sepsis criteria? Chest. 1998 Jun;113(6):1533-41.

[75] Oberhoffer M, Karzai W, Meier-Hellmann A, Bogel D, Fassbinder J, Reinhart K. Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis. Crit Care Med. 1999 Sep;27(9):1814-8.

[76] Oberhoffer M, Vogelsang H, Russwurm S, Hartung T, Reinhart K. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med. 1999 Mar;37(3):363-8.

[77] Hensel M, Volk T, Docke WD, Kern F, Tschirna D, Egerer K, Konertz W, Kox WJ. Hyperprocalcitonemia in patients with noninfectious SIRS and pulmonary dysfunction associated with cardiopulmonary bypass. Anesthesiology. 1998 Jul;89(1):93-104.

[78] Reith HB, Mittelkotter U, Debus ES, Kussner C, Thiede A. Procalcitonin in early detection of postoperative complications. Dig Surg. 1998;15(3):260-5.

[79] Whang KT, Steinwald PM, White JC, Nylen ES, Snider RH, Simon GL, Goldberg RL, Becker KL. Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab. 1998 Sep;83(9):3296-301.

[80] Suprin E, Camus C, Gacouin A, Le Tulzo Y, Lavoue S, Feuillu A, Thomas R. Procalcitonin: a valuable indicator of infection in a medical ICU? Intensive Care Med. 2000 Sep;26(9):1232-8.

[81] Selberg O, Hecker H, Martin M, Klos A, Bautsch W, Kohl J. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med. 2000 Aug;28(8):2793-8.

[82] Sablotzki A, Dehne MG, Friedrich I, Grond S, Zickmann B, Muhling J, Silber RE, Czeslick EG. Different expression of cytokines in survivors and non-survivors from MODS following cardiovascular surgery. Eur J Med Res. 2003 Feb;8(2):71-6.

[83] Sablotzki A, Friedrich I, Muhling J, Dehne MG, Spillner J, Silber RE, Czeslik E. The systemic inflammatory response syndrome following cardiac surgery: different expression of proinflammatory cytokines and procalcitonin in patients with and without multiorgan dysfunctions. Perfusion. 2002 Mar;17(2):103-9.

[84] Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J; Geneva Sepsis Network. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Crit Care Med. 2001 Aug;164(3):396-402.

[85] Spittler A, Razenberger M, Kupper H, Kaul M, Hackl W, Boltz-Nitulescu G, Fugger R, Roth E. Relationship between interleukin-6 plasma concentration in patients with sepsis, monocyte phenotype, monocyte phagocytic properties, and cytokine production. Clin Infect Dis. 2000 Dec;31(6):1338-42.

[86] Khabar KS, elBarbary MA, Khouqeer F, Devol E, al-Gain S, al-Halees Z. Circulating endotoxin and cytokines after cardiopulmonary bypass: differential correlation with duration of bypass and systemic inflammatory response/multiple organ dysfunction syndromes. Clin Immunol Immunopathol. 1997 Oct;85(1):97-103.

[87] Hirai S. Systemic inflammatory response syndrome after cardiac surgery under cardiopulmonary bypass. Ann Thorac Cardiovasc Surg. 2003 Dec;9(6):365-70.

[88] Myc A, Buck J, Gonin J, Reynolds B, Hammerling U, Emanuel D. The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome. Clin Diagn Lab Immunol. 1997 Mar;4(2):113-6.

[89] Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP, Lemke JH. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999 Nov;180(5):1584-9.

[90] Wolk K, Docke WD, von Baehr V, Volk HD, Sabat R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood. 2000 Jul;96(1):218-23.

[91] Kopydlowski KM, Salkowski CA, Cody MJ, van Rooijen N, Major J, Hamilton TA, Vogel SN. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol. 1999 Aug;163(3):1537-44.

[92] VanOtteren GM, Strieter RM, Kunkel SL, Paine R 3rd, Greenberger MJ, Danforth JM, Burdick MD, Standiford TJ. Compartmentalized expression of RANTES in a murine model of endotoxemia. J Immunol. 1995 Feb;154(4):1900-8.

[93] Cavaillon JM, Adib-Conquy M, Fitting C, Adrie C, Payen D. Cytokine cascade in Sepsis. Scand J Infect Dis. 2003;35(9):535-44.

[94] Tamion F, Richard V, Bonmarchand G, Leroy J, Lebreton JP, Thuillez C. Induction of heme-oxygenase-1 prevents the systemic responses to hemorrhagic shock. Crit Care Med. 2001 Nov;164(10 Pt 1):1933-8.

[95] Pellacani A, Wiesel P, Sharma A, Foster LC, Huggins GS, Yet SF, Perrella MA. Induction of heme oxygenase-1 during endotoxemia is downregulated by transforming growth factor-beta1. Circ Res. 1998 Aug;83(4):396-403.

[96] Downard PJ, Wilson MA, Spain DA, Matheson PJ, Siow Y, Garrison RN. Heme oxygenase-dependent carbon monoxide production is a hepatic adaptive response to sepsis. J Surg Res. 1997 Jul;71(1):7-12.

[97] Yet SF, Pellacani A, Patterson C, Tan L, Folta SC, Foster L, Lee WS, Hsieh CM, Perrella MA. Induction of heme oxygenase-1 expression in vascular smooth muscle cells. A link to endotoxic shock. J Biol Chem. 1997 Feb;272(7):4295-301.

[98] Otterbein L, Sylvester SL, Choi AM. Hemoglobin provides protection against lethal endotoxemia in rats: the role of heme oxygenase-1. Am J Respir Cell Mol Biol. 1995 Nov;13(5):595-601.

[99] Chen YH, Yet SF, Perrella MA. Role of heme oxygenase-1 in the regulation of blood pressure and cardiac function. Exp Biol Med (Maywood). 2003 May;228(5):447-53.

[100] Krebs DL, Hilton DJ. SOCS: physiological suppressors of cytokine signaling. J Cell Sci. 2000 Aug;113 (Pt 16):2813-9.

[101] Berlato C, Cassatella MA, Kinjyo I, Gatto L, Yoshimura A, Bazzoni F. Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J Immunol. 2002 Jun;168(12):6404-11.

[102] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 - ΔΔ C T Method. Methods. 2001 Dec;25(4):402-8.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
XDiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
11.04.2006